<div id="readability-page-1">12:14 PM EST, 01/23/2026 (MT Newswires) -- Abbott Laboratories ( ABT ) expects growth to accelerate in the second half of 2026, supported by new product launches, recovering Nutrition and Diagnostics businesses and easier year-over-year comparisons, RBC Capital Markets said.The brokerage said in a Thursday note that the near-term challenges in Diagnostics from Chinese volume-based procurement and internal initiatives in Nutrition are likely to persist in the first half. However, RBC said the issues are temporary.Abbott guided to 2026 organic revenue growth of 6.5% to 7.5%, which is below RBC and consensus estimates. The company also projected adjusted EPS of $5.55 to $5.80 roughly in line with forecasts.MedTech grew 10.4% organically in Q4, which was slightly below RBC's estimate. Established Pharmaceuticals rose 7%. These results supported total organic growth of 3.8% but excluding COVID-related sales.The brokerage said that the expectations have now reset and upside surprises in the second half could come from the US launch of the VOLT system in Electrophysiology. Additional growth could come from Structural Heart, Diabetes and potential M&amp;A in Diagnostics and MedTech.Management remains committed to delivering double-digit EPS growth and cited confidence in operational execution and long-term demand trends, according to the note.RBC maintained an outperform rating for Abbott and lowered its price target to $135 from $147.Price: 107.66, Change: -0.95, Percent Change: -0.88 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

ARKG

Abbott Laboratories anticipates growth in H2 2026, driven by new product launches and a recovery in its Nutrition and Diagnostics sectors, according to RBC Capital Markets. Despite facing near-term challenges, the company projects organic revenue growth of 6.5% to 7.5% and adjusted EPS of $5.55 to $5.80. RBC maintains an outperform rating but has lowered its price target to $135 from $147. MedTech and Established Pharmaceuticals showed growth, contributing to a total organic growth of 3.8%.

fidelity

iShares US Pharma

Abbott Laboratories

Health Care Select Sector SPDR

iShares Global Healthcare

iShares US Medical Devices

SPDR S&P Health Equip

Abacus Global

VG Health

Ark Genomic Revolution ETF

Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says